Hip Innovation Technology
-
Recon
Hip Innovation Technology Announces Positive Clinical Study Data of its Novel Reverse Hip Replacement System for the Treatment of Total Hip Arthroplasty
Data Demonstrates Excellent Fixation with a Predicted Low Risk of Revision at Ten Years Patients Report Very High Levels of Satisfaction…
Read More » -
Recon
Total Hip Arthroplasty — New Advance Changes the Game
Hip Innovation Technology Advances Reverse Hip Replacement System February 9, 2023 – OrthoSpineNews – What are some of the shortcomings…
Read More » -
Recon
Hip Innovation Technology Announces Initiation of FDA Approved Investigational Device Exemption Study
First U.S. Implantation of its Reverse Hip Replacement System for the Treatment of Total Hip Arthroplasty Completed BOCA RATON, Fla., Jan.…
Read More » -
Recon
Hip Innovation Technology Presents Data Demonstrating the Potential Utility of its Novel Hip Replacement System in Addressing Instability Following Total Hip Arthroplasty
BOCA RATON, Fla., July 20, 2022 /PRNewswire/ — Hip Innovation Technology, LLC (HIT), a medical device company developing innovative orthopedic device solutions…
Read More » -
Recon
Hip Innovation Technology Strengthens Senior Leadership Team
Strategic Hires Support Pivotal Study Execution and Future Company Growth BOCA RATON, Fla., Feb. 16, 2022 /PRNewswire/ — Hip Innovation Technology, LLC (HIT),…
Read More » -
Recon
Hip Innovation Technology Receives FDA Investigational Device Exemption (IDE) Approval to Initiate Landmark Study of its Reverse Hip Replacement System
HIT’s Reverse Hip Replacement System may Revolutionize Total Hip Replacement Surgery BOCA RATON, Fla., Jan. 18, 2022 /PRNewswire/ — Hip Innovation Technology, LLC…
Read More » -
Recon
Hip Innovation Technology Initiates Clinical Trial of its Novel Hip Replacement System for the Treatment of Total Hip Arthroplasty
BOCA RATON, Fla., Aug. 9, 2017 /PRNewswire/ — Hip Innovation Technology, LLC (HIT), a medical device company developing innovative orthopedic device solutions to…
Read More »